Percutaneous Trigger Finger Release Concomitant Steroid Injection Versus Percutaneous Trigger Finger Release Alone

Material and Methods

Study Population:

Patients diagnosed with trigger finger, aged 18 years or older, and classified under Quinell's grade 2, 3, or 4, were included in the study [ ]. Recruitment took place at the Outpatient Orthopedic Department of the Police General Hospital between October 2023 and January 2024. Exclusion criteria encompassed individuals with a history of prior hand surgery, Dupuytren's disease, type 1 diabetes, previous phalangeal fractures, recent steroid injection within the last month, and autoimmune diseases.

Group allocation and Randomization:

Patients were enrolled and randomized into two groups, percutaneous A1 pulley release with steroid injection (Group A) and percutaneous A1 pulley release alone (Group B), by utilizing computer generate randomization and the results were put in opaque sealed envelopes. Informed consent was obtained from all participants, and surgeries were performed by the same surgeon (WJ).

Surgical Technique:

The surgical procedure followed Eastwood's method [ ], involving the following steps:

• Preparation of the sterile field.
• Injection of 1% lidocaine with epinephrine at the surgical site.
• Insertion of an 18-gauge needle following the tract from the previous injection.
• Patient extension of the finger to bring flexor tendons close to the skin, moving the neurovascular structures away.
• Slow penetration of the needle until it is over the A1 pulley.
• Gentle flexion of the finger while observing the needle tip to prevent penetrating the flexor tendon.
• Rotation of the needle bevel into a longitudinal orientation to the flexor tendon.
• Release of the A1 pulley by moving the needle upward and downward parallel to the flexor tendon until complete release is achieved.
• Withdrawal of the needle while hyperextending the finger.
• Flexion and extension of the finger to check for triggering.
• Injection of triamcinolone (40mg/ml) 1 ml in the study group.
• Closure of the wound with a small elastic dressing.

Postoperative Protocols:

Both groups received identical postoperative protocols, including the same medications (Augmentin, Naproxen, Tolperisone) for 7 days. Patients were encouraged for early finger range of motion without restriction.

Outcome Measures:

The primary outcome measure was pain score assessed by the VAS. Secondary outcomes included quality of life measured by the qDASH score, patient satisfaction, and surgical complications.

Follow-Up:

All cases underwent follow-up via telephone on postoperative days 1 to 6, in the clinic during the first and second weeks, and at 1 to 2 months postoperative.

Statistical analysis In this study, all data calculations were conducted using Stata software (version 17.0). Group comparisons involved the application of Pearson's chi-squared test or Continuity Correction chi-squared test for categorical variables, and the student's t-test was employed for continuous variables. Statistically significant differences were defined as those with a P-value < 0.05.

Inclusion criteria

• clinical diagnosis of trigger finger
• aged 18 years or older
• trigger finger are classified under Quinell's grade 2, 3, or 4

Exclusion criteria

• a history of prior hand surgery
• Dupuytren's disease
• type 1 diabetes
• previous phalangeal fractures
• recent steroid injection within the last month
• autoimmune diseases